- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial | 94 | PR Newswire | Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor... ► Artikel lesen | |
| Fr | Why Electro Optic Systems, Megaport, Racura, and Xero shares are racing higher today | 13 | The Motley Fool Australia | ||
| Fr | Daily Special: Racura Oncology, AVITA Medical, Archer Materials, Resolution Minerals | 9 | Finance News Network | ||
| Fr | Racura Oncology Advances CPACS Trial to Next Dose Level | 1 | smallcaps.com.au | ||
| Fr | RACURA ONCOLOGY LTD: CPACS Trial Cleared to Escalate to Next RC220 Dose Level | - | ASX | ||
| Do | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| Do | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 08.05. | RACURA ONCOLOGY LTD: Racura Oncology Options Expiry Reminder | - | ASX | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.05. | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 07.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 04.05. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 30.04. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 29.04. | RACURA ONCOLOGY LTD: March 2026 Quarterly Activity Report and Appendix 4C | - | ASX | ||
| 29.04. | RACURA ONCOLOGY LTD: Racura and Wollongong Uni Granted NSW TechVoucher | - | ASX | ||
| 24.04. | RACURA ONCOLOGY LTD: Notification of cessation of securities - RAC | - | ASX | ||
| 23.04. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 22.04. | Racura Oncology Presents Key MYC Silencing Data at Major Cancer Conference | 1 | Finance News Network | ||
| 22.04. | RACURA ONCOLOGY LTD: Racura presents MYC silencing data at AACR 2026 | - | ASX | ||
| 16.04. | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 09.04. | RACURA ONCOLOGY LTD: Racura Singapore and HK Investor Briefing Update | - | ASX |
1 2 3 4 5 Weiter >>
91 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 62,93 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| QIAGEN | 28,600 | +0,04 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| GEOVAX LABS | 2,220 | +80,49 % | Morning Market Movers: Sunshine Biopharma, GeoVax Labs, Huachen AI Parking Management Technology, LiveRamp See Big Swings | BEIJING (dpa-AFX) - At 8:15 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,810 | 0,00 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| ERASCA | 10,270 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 320,87 | +0,11 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| DESIGN THERAPEUTICS | 10,700 | 0,00 % | Design Therapeutics, Inc.: Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia | DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,010 | -5,10 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| TANGO THERAPEUTICS | 20,660 | +0,49 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,76 | -2,93 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| RECURSION PHARMACEUTICALS | 2,895 | -1,19 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| ENLIVEN THERAPEUTICS | 39,630 | 0,00 % | Enliven to present updated ELVN-001 leukemia trial data at EHA | ||
| CULLINAN THERAPEUTICS | 14,870 | 0,00 % | Tazi and Bachiri Elected to Lead CGEM with 91.5% of the Vote | ||
| COGENT BIOSCIENCES | 31,360 | -4,04 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress | ||
| TAYSHA GENE THERAPIES | 5,445 | 0,00 % | Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 Highlights |
Das Unternehmen RACURA ONCOLOGY LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.